Recurrence free survival | Overall survival | |||||||
---|---|---|---|---|---|---|---|---|
95,0% CI for HR | 95,0% CI for HR | |||||||
Sig. | HR | Lower | Upper | Sig. | HR | Lower | Upper | |
Age at primary diagnosis | 0.248 | 1.00 | 0.99 | 1.00 | < 0.001 | 1.05 | 1.04 | 1.06 |
Tumor size (mm) | < 0.001 | 1.01 | 1.00 | 1.01 | < 0.001 | 1.01 | 1.00 | 1.01 |
Intrinsic sub types | < 0.001 | < 0.001 | ||||||
Luminal B/HER2- | < 0.001 | 2.01 | 1.54 | 2.61 | < 0.001 | 1.72 | 1.38 | 2.15 |
Luminal B/HER2+ | 0.003 | 1.61 | 1.18 | 2.21 | 0.010 | 1.42 | 1.09 | 1.86 |
TNT | < 0.001 | 3.55 | 2.63 | 4.79 | < 0.001 | 2.96 | 2.27 | 3.87 |
HER2 overexpressing | < 0.001 | 3.35 | 2.39 | 4.70 | < 0.001 | 2.07 | 1.47 | 2.91 |
Guideline-adherent hormonal therapy | < 0.001 | 1.91 | 1.43 | 2.55 | < 0.001 | 2.00 | 1.59 | 2.52 |
Guideline-adherent chemotherapy | < 0.001 | 1.84 | 1.46 | 2.31 | < 0.001 | 1.83 | 1.51 | 2.22 |